Provider Response to Critical Action Values for Hypoglycemia in the Ambulatory Setting: a Retrospective Cohort Study
- PMID: 32935316
- PMCID: PMC8131438
- DOI: 10.1007/s11606-020-06225-y
Provider Response to Critical Action Values for Hypoglycemia in the Ambulatory Setting: a Retrospective Cohort Study
Abstract
Background: The blood glucose level triggering a critical action value (CAV) for hypoglycemia is not standardized, and associated outcomes are unknown.
Objective: To evaluate the clinical consequences of, and provider responses to, CAVs for hypoglycemia.
Design: Retrospective cohort study at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center between April 1, 2013, and January 31, 2017.
Participants: Patients with an ambulatory serum glucose < 50 mg/dL. Point-of-care capillary glucose and whole blood glucose samples were excluded.
Main measures: Electronic medical record (EMR) review for providers' documented response to CAV, associated patient symptoms, and serious adverse events.
Key results: We analyzed 209 CAVs for hypoglycemia from 154 patients. The median age (IQR) was 59 years (46, 69), 89 (57.8%) were male, and 96 (62.3%) were black. Provider-to-patient contact occurred in 128 of 209 (61.2%) episodes, among which no documented etiology was observed for 81 of 128 (63.3%), no recommendations were provided in 32 of 128 (25.0%), and no patient-reported hypoglycemic symptoms were documented in 103 of 128 (80.5%). Serious adverse events were documented in 4 of 128 episodes (3.1%), two required glucagon administration, and three required an ED visit. Provider-to-patient contact was associated with the patient having malignant neoplasm (adjusted OR 3.63, p = 0.045) or a hypoglycemic disorder (adjusted OR 7.70, p = 0.018) and inversely associated with a longer time from specimen collection to EMR result (adjusted OR 0.90 per hour, p = 0.016).
Conclusions: There is inconsistent provider-to-patient contact following CAVs for hypoglycemia, and the etiology and symptoms of hypoglycemia were infrequently documented. There were few serious documented adverse events associated with hypoglycemia, although undocumented events may have occurred, and the incidence of serious adverse events in non-contacted patients remains unknown. These findings demonstrate a need to standardize provider response to CAVs for hypoglycemia. Decreasing the lag time between sample collection and laboratory result reporting may increase provider-to-patient contact.
Keywords: Ambulatory; Critical action value; Glucose; Hypoglycemia.
Conflict of interest statement
Nestoras Mathioudakis was supported by grant K23DK111986-01 from the National Institute for Diabetes and Digestive and Kidney Diseases. The authors declared that there is no potential conflict of interest.
Similar articles
-
Current practice of hypoglycemia management in the ED.Am J Emerg Med. 2017 Jan;35(1):87-91. doi: 10.1016/j.ajem.2016.10.009. Epub 2016 Oct 8. Am J Emerg Med. 2017. PMID: 27832978
-
Hypoglycemic risk exposures in relation to low serum glucose values in ambulatory patients.Medicine (Baltimore). 2020 Jan;99(2):e18679. doi: 10.1097/MD.0000000000018679. Medicine (Baltimore). 2020. PMID: 31914062 Free PMC article.
-
Development and Validation of a Machine Learning Model to Predict Near-Term Risk of Iatrogenic Hypoglycemia in Hospitalized Patients.JAMA Netw Open. 2021 Jan 4;4(1):e2030913. doi: 10.1001/jamanetworkopen.2020.30913. JAMA Netw Open. 2021. PMID: 33416883 Free PMC article.
-
Hypoglycemia warning signal and glucose sensors: requirements and concepts.Diabetes Technol Ther. 2003;5(4):563-71. doi: 10.1089/152091503322250587. Diabetes Technol Ther. 2003. PMID: 14511411 Review.
-
Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents.Front Endocrinol (Lausanne). 2021 Mar 8;12:571568. doi: 10.3389/fendo.2021.571568. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33763024 Free PMC article.
References
-
- Group IHS Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155–157. doi: 10.2337/dc16-2215. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous